Empowering

people living with

rare immunologic diseases

We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.

Media

Our latest announcements

Read all press releases

Hansa Biopharma appoints Fredrik Röök as VP Business Development

10/06/2026

Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York

02/06/2026

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

Regulatory press release

01/06/2026

Hansa Biopharma’s CEO Renée Aguiar-Lucander named one of Sweden’s Most Influential Business Women of 2026

29/05/2026

Our science

Our unique antibody-cleaving enzyme technology

Our proprietary antibody-cleaving enzymes imilfidase and HNSA-5487 target and inactivate IgG antibodies in the blood and tissues, inhibiting the IgG-mediated immune responses, helping halt the progression of IgG-driven acute autoimmune diseases, as well as enable lifesaving and life altering procedures and therapies.

Science

Pipeline

Our focus area

We aim to address unmet need in conditions where the IgG-driven immune response becomes harmful, or it interferes with the delivery of lifesaving and life altering therapies.

Autoimmune diseases

Desensitization in gene therapy

Desensitization in transplantation

PATIENT STORY

Cris Ann’s Story: fighting for a chance to live

Soon after being told she had kidney disease, Cris Ann learned she is one of the 10-15% of kidney transplant patients in the U.S. who are highly sensitized, making it virtually impossible to find a compatible donor kidney. This is her story.

Read the story